NCT01394991 - A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia | Biotech Hunter

Enrollment

504

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

AnemiaNeoplasms

Interventions

DRUG

Epoetin alfa 450 IU/kg once a week

450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

DRUG

Epoetin alfa 150 IU/kg 3 times a week

150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

DRUG

Epoetin alfa 450 IU/kg once a week (QW)

450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks

DRUG

Epoetin alfa 150 IU/kg 3 times a week (TIW)

150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY